Abstracts tagged "Diagnosis and rheumatic disease"

Abstract Number: 247 • 2018 ACR/ARHP Annual Meeting
Fibromyalgia Patients Often Receive Several Rheumatic Disease Diagnoses
Robert S. Katz¹ and Jessica L. Polyak², ¹Rush University Medical Center, Chicago, IL, ²Rheumatology Associates S.C., Chicago, IL
Background/Purpose: In a written office questionnaire, we asked patients the number of rheumatic disease diagnoses they had been given. We also asked about the length…
Abstract Number: 1023 • 2017 ACR/ARHP Annual Meeting
The Autoimmune Discovery Ichip Distinguishes Healthy Individuals (HC) from Those with SLE, Rheumatoid Arthritis (RA), Scleroderma (SSc), Sjogren’s Syndrome (SS), and the Anti-Phospholipid Syndrome (APS)
Chaim Putterman¹, Armando Gabrielli², Alexandra Balbir-Gurman³, Pennina Safer⁴, Keren Jakobi-Brook⁴, Rachel Sorek⁴, Ilana Gluzman⁴, Steve Wallace⁵ and Irun R. Cohen^4,6, ¹Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY, ²Istituto di Clinica Medica dell'Università di Ancona, Ancona, Italy, Ancona, Italy, ³Rheumatology Unit, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion, Haifa, Israel, Haifa, Israel, ⁴ImmunArray Ltd., Rehovot, Israel, Rehovot, Israel, ⁵ImmunArray Inc., VA, USA, Richmond, VA, ⁶Weizmann Institute of Science, Rehovot, Israel, Rehovot, Israel
Background/Purpose: Current serological tests are not sufficiently accurate in differentiating between HC and those with autoimmune rheumatic diseases. We developed the iCHIP antigen microarray to…
Abstract Number: 2063 • 2012 ACR/ARHP Annual Meeting
Detection of Inflammatory Arthritis and Musculoskeletal Conditions in a First Nations Community: Results of an Onsite Screening Program
Cheryl Barnabe¹, Carrissa Low Horn², Margaret Kargard², Stephen Mintsioulis², Sharon Leclercq³, Dianne P. Mosher⁴, Hani S. El-Gabalawy⁵, Tyler White² and Marvin J. Fritzler⁶, ¹Medicine, Community Health Sciences, University of Calgary, Calgary, AB, Canada, ²Siksika Health Services, Siksika, AB, Canada, ³Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ⁴Med, University of Calgary, Calgary, AB, Canada, ⁵Arthritis Centre, University of Manitoba, Winnipeg, MB, Canada, ⁶Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: RA and SLE are more severe and at least twice as prevalent in the First Nations population of Canada compared to the Caucasian population.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].